Evaluation of CEP-701 [lestaurtinib], an Orally Available JAK2 [Janus kinase 2] Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis.

Trial Profile

Evaluation of CEP-701 [lestaurtinib], an Orally Available JAK2 [Janus kinase 2] Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2012

At a glance

  • Drugs Lestaurtinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2010 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 08 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top